Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Two-year carcinogenicity studies with the oral direct thrombin inhibitor ximelagatran in the rat and the mouse.

Stong DB, Carlsson SC, Bjurström S, Fransson-Steen R, Healing G, Skånberg I.

Int J Toxicol. 2012 Jul-Aug;31(4):348-57. doi: 10.1177/1091581812448881. Epub 2012 Jun 12.

PMID:
22692977
2.

Assessment of biomarkers of drug-induced kidney injury in cynomolgus monkeys treated with a triple reuptake inhibitor.

Guha M, Heier A, Price S, Bielenstein M, Caccese RG, Heathcote DI, Simpson TR, Stong DB, Bodes E.

Toxicol Sci. 2011 Apr;120(2):269-83. doi: 10.1093/toxsci/kfr013. Epub 2011 Jan 22.

PMID:
21258088
3.

Lack of trophic pancreatic effects in humans with long-term administration of ximelagatran.

Liddle RA, Toskes PP, Horrow J, Ghali J, Dachman A, Stong D.

Pancreas. 2006 Mar;32(2):205-10.

PMID:
16552342
4.

Systemic administration of rhIGF-I enhanced regeneration after sciatic nerve crush in mice.

Contreras PC, Steffler C, Yu E, Callison K, Stong D, Vaught JL.

J Pharmacol Exp Ther. 1995 Sep;274(3):1443-9.

PMID:
7562520
5.

Insulin-like growth factor-I: potential for treatment of motor neuronal disorders.

Lewis ME, Neff NT, Contreras PC, Stong DB, Oppenheim RW, Grebow PE, Vaught JL.

Exp Neurol. 1993 Nov;124(1):73-88. Review.

PMID:
8282084
6.

Effects of multiple subcutaneous doses of rhIGF-1 on total and free IGF-1 levels and blood glucose in humans.

Stong DB, Raskin R.

Ann N Y Acad Sci. 1993 Aug 27;692:317-20. No abstract available.

PMID:
8215041
10.

The metabolism of dibenz[a,j]acridine in the isolated perfused lung.

Warshawsky D, Hollingsworth L, Reilman R, Stong D.

Cancer Lett. 1985 Sep 30;28(3):317-26.

PMID:
4053001

Supplemental Content

Support Center